CVS Caremark (CVS) Tops Q2 EPS by 1c; Narrows FY11 Outlook
Tweet
Share
E-mail
Get Alerts CVS Hot Sheet
Price: $88.84 -1.58%
EPS Growth %: +2.5%
Financial Fact:
Cost of revenues: 37.12B
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +2.5%
Financial Fact:
Cost of revenues: 37.12B
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
CVS Caremark (NYSE: CVS) reported Q2 EPS of $0.65, $0.01 better than the analyst estimate of $0.64. Revenue for the quarter came in at $26.6 billion versus the consensus estimate of $26.76 billion.
Sees FY2011 EPS of $2.75-$2.81, versus prior guidance of $2.72-$2.82 and the consensus of $2.78.
UPDATE - from its Q2 conference call: sees Q3 adj-EPS of 66-68c, vs. the consensus of 68c.
Sees FY2011 EPS of $2.75-$2.81, versus prior guidance of $2.72-$2.82 and the consensus of $2.78.
UPDATE - from its Q2 conference call: sees Q3 adj-EPS of 66-68c, vs. the consensus of 68c.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aetna expands bundled cancer prior authorizations for Medicaid members
- Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh
- Aetna expands bundled oncology prior authorizations, easing provider burden and accelerating member access to care
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
